Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance.

Abstract

Defective apoptosis signaling and multidrug resistance are major barriers for successful cancer treatment. To identify drugs capable of targeting treatment-resistant cancer cells, we screened small-molecule kinase inhibitor libraries for compounds that decrease the viability of apoptosis-resistant human MCF7-Bcl-2 breast cancer cells. SU11652, a… (More)
DOI: 10.1158/1535-7163.MCT-13-0084

Topics

6 Figures and Tables

Cite this paper

@article{Ellegaard2013SunitinibAS, title={Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance.}, author={Anne-Marie Ellegaard and Line Groth-Pedersen and Viola Oorschot and Judith Klumperman and Thomas Kirkegaard and Jesper Nylandsted and Marja J{\"a}{\"a}ttel{\"a}}, journal={Molecular cancer therapeutics}, year={2013}, volume={12 10}, pages={2018-30} }